<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03162458</url>
  </required_header>
  <id_info>
    <org_study_id>MMH-AD-006</org_study_id>
    <nct_id>NCT03162458</nct_id>
  </id_info>
  <brief_title>Clinical Trial of Efficacy and Safety of Anaferon for Children Liquid Dosage Form in the Treatment of Acute Upper Respiratory Infections</brief_title>
  <official_title>Multicenter Double-blind Placebo-controlled Parallel Group Randomized Clinical Trial of Efficacy and Safety of Anaferon for Children Liquid Dosage Form in the Treatment of Acute Upper Respiratory Infections</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Materia Medica Holding</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Materia Medica Holding</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Purpose of the study:

        -  To assess efficacy of Anaferon for children liquid dosage form in the treatment of acute
           upper respiratory tract infections.

        -  To assess safety of Anaferon for children liquid dosage form in the treatment of acute
           upper respiratory tract infections.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 22, 2015</start_date>
  <completion_date type="Actual">April 29, 2015</completion_date>
  <primary_completion_date type="Actual">April 29, 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>• Average illness duration (the interval between the start of the trial treatment and the time when recovery/improvement - based on patient diary data)</measure>
    <time_frame>From the time of randomization until the time of recovery/improvement, assessed up to 14 days</time_frame>
    <description>based on patient diary data</description>
  </primary_outcome>
  <primary_outcome>
    <measure>• Severity of illness (adjusted area under the curve for the total severity index on Days 1-5, based on patient diary data)</measure>
    <time_frame>On Days 1-5 of observation</time_frame>
    <description>based on the data on area under curve for total index of severity of general symptoms and nasal/ throat/ chest symptoms on Days 1-5 of observation - based on patient diary data</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients with recovery on Days 2, 3, 4 and 5 of observation (based on patient diary data)</measure>
    <time_frame>On Days 1-5 of the treatment</time_frame>
    <description>based on patient diary data</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average duration of fever (i.e. body temperature &gt;37.3°С)</measure>
    <time_frame>From the time of randomization until the time of normal body temperature, assessed up to 14 days</time_frame>
    <description>based on patient diary data</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>• Mean body temperatures, measured in the morning and evening on Days 2-5 (based on patient diary data)</measure>
    <time_frame>On Days 2-5 of the treatment</time_frame>
    <description>based on patient diary data</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients with body temperature ≤37.30С on Days 2-5 of observation</measure>
    <time_frame>On Days 2-5 of observation</time_frame>
    <description>based on patient diary data</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total severity index on Days 2-5 of observation based on patient diary data; on Days 3 and 6 of observation based on the results of doctor's examination</measure>
    <time_frame>On Days 2-6 of the treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severity of illness (adjusted area under the curve for the total severity index on Days 1, 3, and 6 of observation, based on the results of doctor's examination)</measure>
    <time_frame>on Days 1, 3, 6</time_frame>
    <description>based on the data on area under curve for total index of severity of general symptoms and nasal/ throat/ chest symptoms on Days 1, 3, 6 based on the results of doctor's examination</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of antipyretic use (for prescribed indications) on Days 1-5 of treatment (based on patient diary data)</measure>
    <time_frame>on Days 1-5 of treatment</time_frame>
    <description>based on patient diary data</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients with complications of illness, including those requiring antibiotic administration or hospitalization) for 14 days of observation</measure>
    <time_frame>From the time of randomization up to 14 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">142</enrollment>
  <condition>Acute Upper Respiratory Infections</condition>
  <arm_group>
    <arm_group_label>Anaferon for children</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anaferon for children (liquid dosage form)</intervention_name>
    <description>10 drops per dose. Day 1: 10 drops every 30 minutes for the first 2 hours, followed by three more doses regularly spaced during the rest of the day. Day 2 to 5: 10 drops three times daily.</description>
    <arm_group_label>Anaferon for children</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo (liquid dosage form)</intervention_name>
    <description>10 drops per dose. Day 1: 10 drops every 30 minutes for the first 2 hours, followed by three more doses regularly spaced during the rest of the day. Day 2 to 5: 10 drops three times daily.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients of both sexes aged 1 month to 3 years.

          2. Diagnosis of acute upper respiratory infection based on a doctor's examination of the
             patient: body temperature at least 37.8°C when visiting a doctor + symptom scores ≥3
             (presence of at least 1 general symptom and 1 nasal/ throat/chest symptom).

          3. The first 24 hours from the beginning of manifestations of acute upper respiratory
             infection.

          4. Acute respiratory viral infections season.

          5. The possibility to start treatment within 24 hours of the onset of acute upper
             respiratory infection symptoms.

          6. Availability of a patient information sheet (Informed Consent form) signed by the
             patient's parents/adopters to confirm the child's participation in the clinical trial
             signed by one parent/adopter of patient.

        Exclusion Criteria:

          1. Suspected pneumonia or bacterial infection or the presence of a disease requiring
             usage of antibacterial drugs starting from day 1 of the illness onset.

          2. Clinical symptoms of severe influenza/ARI (acute respiratory infection) requiring
             hospitalization.

          3. Suspected early manifestations of diseases that have symptoms similar to ARI symptoms
             (other infectious diseases, influenza-like syndrome at the onset of systemic
             connective tissue disorders, hematologic neoplasms and other pathology).

          4. Documented (prior diagnosis) or suspected disease such as

               -  primary or secondary immunodeficiency: а) lymphoid immunodeficiency (T-cell
                  and/or B-cell immunity, immunodeficiencies with predominant antibody deficit, b)
                  phagocyte deficits; c) complement factor deficit; d) combined immunodeficiency
                  including AIDS secondary to HIV infection; toxic, autoimmune, infectious, or
                  radial panleukopenia syndrome; general lymphocytopenia syndrome; syndrome of
                  lymphocyte polyclonal activation; postsplenectomia syndrome; congenital asplenia;
                  syndrome of immune complexes pathology associated with infectious, autoimmune and
                  allergic diseases;

               -  cystic fibrosis, primary ciliary dyskinesia, bronchopulmonary dysplasia,
                  congenital malformations of the respiratory system, including malformations of
                  upper respiratory tract, and other chronic lung disease;

               -  malignant neoplasm.

          5. Exacerbation or decompensation of chronic diseases affecting ability to participate in
             the clinical study.

          6. Medical history of polyvalent allergy.

          7. Allergy/ intolerance to any of the components of medications used in the treatment.

          8. Use of medications listed in 'Prohibited concomitant treatments/medications' within 2
             weeks before study entry.

          9. Drug use or alcohol use (more than 2 alc. units daily) by the patient's
             parent(s)/adopter(s).

         10. Mental disorders of patient's parent(s)/adopter(s).

         11. Patients whose parents/adopters, from the investigator's point of view, will fail to
             comply with the observation requirements of the trial or with the intake regimen of
             the investigated medicines.

         12. Participation in other clinical studies in the course of 3 months (or 1-2 months for
             infants under two months of age) prior to the inclusion in the trial.

         13. Patient's parents/adopters are related to the clinical trial site's research staff
             directly involved in the trial or are the immediate family member of the researcher.
             The immediate family members include husband/wife, parents, children or brothers (or
             sisters), regardless of whether they are natural or adopted.

         14. The patient's parent/adopter works for OOO &quot;NPF &quot;MATERIA MEDICA HOLDING&quot; (i.e., the
             company's employee, part-time employee under contract or appointed official in charge
             of the trial, or their immediate family).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Month</minimum_age>
    <maximum_age>3 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>LLC Center for Vaccine Prevention &quot;DIAVAKS&quot;</name>
      <address>
        <city>Moscow</city>
        <zip>129515</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Municipal Health Care Institution &quot;City Child Health Clinical Polyclinic №5&quot;</name>
      <address>
        <city>Perm</city>
        <zip>614066</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Petersburg State Budgetary Health Care Institution &quot;Сity Polyclinic №44&quot;</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>192212</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Petersburg State Health Care Institution &quot;Children's City Polyclinic No. 45 Nevsky District&quot;</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>193312</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alliance Biomedical-Russian Group LLC</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>194356</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Petersburg State Budgetary Healthcare Institution &quot;Children's City Hospital No. 22&quot;</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>196650</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Federal State Budgetary Educational Institutionof Higher Education &quot;Yaroslavl State Medical University&quot; of the Ministry of Healthcare of the Russian Federation</name>
      <address>
        <city>Yaroslavl</city>
        <zip>150000</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 19, 2017</study_first_submitted>
  <study_first_submitted_qc>May 19, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 22, 2017</study_first_posted>
  <last_update_submitted>May 19, 2017</last_update_submitted>
  <last_update_submitted_qc>May 19, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 22, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Respiratory Tract Infections</mesh_term>
  </condition_browse>
  <pending_results>
    <submitted>May 24, 2017</submitted>
    <returned>October 17, 2017</returned>
    <submitted>October 30, 2017</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

